Vitamin E as an antioxidant/free radical scavenger against amyloid β-peptide-induced oxidative stress in neocortical synaptosomal membranes and hippocampal neurons in culture: Insights into Alzheimer's disease

Reviews in the Neurosciences

Volumn 10, Issue 2, 1999, Pages 141-149

  Butterfield, D Allan ^a,b   Koppal, Tanuja ^a   Subramaniam, Ram ^a   Yatin, Servet ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Amyloid peptide; Free radicals; Lipid peroxidation; Neurotoxicity; Oxidative stress; Protein oxidation; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; FREE RADICAL; PROTEIN; SCAVENGER;

ALZHEIMER DISEASE; ENZYME ACTIVITY; HIPPOCAMPUS; HUMAN; HUMAN CELL; LIPID PEROXIDATION; NEOCORTEX; NERVE CELL CULTURE; NEUROTOXICITY; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SYNAPTIC MEMBRANE;

EID: 0032799823     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVNEURO.1999.10.2.141     Document Type: Review

References (64)

1. Avdulov NA, Chochina SV, Igbauboa U, O'Hare EO, Schroeder F, Cleary JP, Wood GP. Amyloid beta-peptides increase annular and bulk fluidity and induce lipid peroxidation in brain synaptic plasma membranes. J Neurochem 1997; 68: 2086-2091.
2. Behl C, Davis J, Cole GM, Schubert D. Vitamin E protects nerve cells from amyloid β-protein toxicity. Biochem Biophys Res Comm 1992; 186: 944-952.
3. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid β protein toxicity. Cell 1994; 77: 817-827.
4. Behl C, Holsboer F. Oxidative stress in the pathogenesis of Alzheimer's disease and antioxidant neuroprotection. Fortschr Neurol Psychiatr 1998; 66: 113-121.
5. Bruce-Keller AJ, Begley JG, Fu W, Butterfield DA, Bredesen DE, Hutchins JB, Hensley K, Mattson MP. Bc1-2 protects isolated plasma and mitochondrial membranes against lipid peroxidation induced by hydrogen peroxide and amyloid beta-peptide. J Neurochem 1998; 70: 31-39.
6. Bush AI, Tanzi RE, Multhap G, Hartshorn M, Saunders AJ, Atwood CS, Hunag X. PrP and Aβ share a common mechanism of metal-dependent reactive oxygen species production. Soc Neurosci Abstr 1998; 508.
7. Butterfield DA. Spin labeling in disease. In: Berliner LJ, ed. Biological Magnetic Resonance. New York: Plenum Press, 1982; 4: 1-78.
8. Butterfield DA, Hensley K, Harris M, Mattson MP, Carney JM. β-Amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: Implications to Alzheimer's disease. Biochem Biophys Res Comm 1994; 200: 710-715.
9. 2+, nitroxide spin probes, and synaptosomal membrane proteins. Life Sci 1996; 58: 217-228.
10. Butterfield DA, Howard BJ, Yatin S, Allen KL, Carney JM. Free radical oxidation of brain proteins in accelerated senescence and its modulation by N-tert-butyl-α-phenylnitrone (PBN). Proc Natl Acad Sci USA 1997; 94: 674-678.
11. Butterfield DA, Hensley K, Cole P, Subramaniam R, Aksenov M, Aksenova M, Bummer PM, Haley BE, Carney JM. Oxidatively-induced structural alteration of glutamine synthetase assessed by analysis of spin labeled incorporation kinetics: Relevance to Alzheimer's disease. J Neurochem 1997; 68: 2451-2457.
12. Butterfield DA. β-Amyloid-associated free radical oxidative stress and neurotoxicity: Implications for Alzheimer's disease. Chem Res Toxicol 1997; 10: 495-506.
13. Butterfield DA, Stadtman ER. Protein oxidation processes in aging brain. Adv Cell Aging Gerontol 1997; 2: 161-191.
14. Daniels WMC, Van Rensberg SJ, van Szyl JM, Taijard JJF. Melatonin prevents β-amyloid-induced lipid peroxidation. J Pineal Res 1998; 24: 78-82.
15. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Rad Biol Med 1991; 11: 81-128.
16. Fu W, Luo H, Parthasarathy S, Mattson MP. Catecholamines potentiate amyloid β-peptide neurotoxicity: involvement of oxidative stress, mitochondrial dysfunction, and perturbed calcium homeostasis. Neurobiol Dis 1998; 5: 229-243.
17. Games D, Adams D, Alessandrinl R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagoplan S, Johnson-Wood K, Khan K, Lee M, Lelbowitz E, McConlogue S, Montoya-Zavalal M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Synder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhao J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995; 373: 523-527.
18. Goodman Y, Mattson MP. Secreted forms of β-amyloid precursor protein protect hippocampal neurons against amyloid β-peptide-induced oxidative injury. Exp Neurol 1994; 128: 1-12.
19. Gridley KE, Green PS, Simpkins JW. Low concentration of estradiol reduce β-amyloid (25-35)-induced toxicity, lipid peroxidation, and glucose utilization in human SK-N-SH neuroblastoma cells. Brain Res 1997; 778: 158-165.
20. Gwebu ET, Williams J, Mathis D, Warden JA, Selassie M, Richardson S, Gwebu NT. Cytotoxicity of β-amyloid peptide 25-35 on vascular smooth muscle cells and attenuation by vitamin E. In Vitro Cell Dev Biol Anim 1997; 33: 672-673.
21. Hall NC, Carney JM, Cheng MS, Butterfield DA. Ischemia/reperfusion induced changes in membrane proteins and lipids of gerbil cortical synaptosomes. Neuroscience 1995; 64: 81-89.
22. Hall K, Dempsey RJ, Carney JM, Donaldson DL, Butterfield DA. Structural alterations in synaptosomal membrane-associated proteins and lipids by transient middle cerebral artery occulusion in the cat. Neurochem Res. 1995; 20: 1161-1169.
23. Hall NC, Carney JM, Cheng MS, Butterfield DA. Prevention of ischemica/-reperfusion-induced alterations in synaptosomal membrane-associated proteins and lipids by N-tert-butyl-β-phenylnitrone and difluoromethylornithine. Neuroscience 1995; 69: 591-600.
24. Hall NC, Carney JM, Plante OJ, Cheng M, Butterfield DA. Effect of 2-cyclohexene-1-one-induced glutathione diminution on ischemia/reperfusion-induced alterations in the physical state of brain synaptosomal membrane proteins and lipids. Neuroscience 1997; 77: 283-290.
25. Harris ME, Hensley K, Butterfield DA, Leedle RE, Carney JM. Direct evidence of oxidative injury by the Alzheimer's amyloid β-peptide in cultured hippocampal neurons. Exp Neurol 1995; 131: 193-202.
26. Harris ME, Carney JM, Cole PS, Hensley K, Howard BJ, Martin LJ, Bummer PM, Wang Y, Pedigo NW Jr, Butterfield DA. β-Amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: implications to Alzheimer's disease. NeuroReport 1995; 6: 1875-1879.
27. Hensley K, Carney J, Mattson M, Aksenova M, Harris M, Wu JF, Floyd R, Butterfield DA. A new model for β-amyloid aggregation and neurotoxicity based on free radical generating capacity of the peptide. Proc Natl Acad Sci USA 1994; 91: 3270-3274.
28. Hensley K, Hall N, Shaw W, Carney JM, Butterfield DA. Electron paramagnetic resonance investigation of free radical induced alterations in neocortical synaptosomal membrane protein infrastructure. Free Rad Biol Med 1994; 17: 321-331.
29. Hensley K, Hall N. Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM, Lovell M, Markesbery WR, Butterfield DA. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995; 65: 2146-2156.
30. Hensley K, Aksenova M. Carney JM. Harris M. Butterfield DA. Amyloid β-peptide spin trapping I: Peptide enzyme toxicity is related to free radical spin trap reactivity. NeuroReport 1995; 6: 489-492.
31. Hensley K, Aksenova M, Carney JM, Harris M, Butterfield DA. Amyloid β-peptide spin trapping II: Evidence for decomposition of the PBN spin adduct. NeuroReport 1995; 6: 493-496.
32. Howard BJ, Yatin S, Hensley K, Allen KL, Kelly JP, Carney JM, Butterfield DA. Prevention of hyperoxia-induced alterations in synaptosomal membrane-associated proteins by N-tert-butyl-α-phenylnitrone and 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl (tempol). J Neurochem 1996; 67: 2045-2050.
33. Janzen EG. A critical review of spin trapping in biological systems. Free Rad Biol Med 1980; 4: 115-154.
34. Jen LS, Hart AJ, Jen A, Relvas JB, Gentleman SM. Alzheimer's peptide kills cells of retina in vivo. Nature 1998; 392: 140-141.
35. Katzman R, Saitoh R. Advances in Alzheimer's disease. FASEB J 1991; 4: 278-286.
36. Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, Mattson MP. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid β-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 1997; 69: 273-284.
37. Koppal T, Subramaniam R, Drake J, Prasad RP, Dhillon H, Butterfield DA. Vitamin E protects against Alzheimer's amyloid peptide (25-35)-induced changes in neocortical synaptosomal membrane lipid structure and composition. Brain Res 1998; 786: 270-273.
38. Lockhart BP, Benicourt C, Junien JL, Privat A. Inhibitors of free radical formation fail to attenuate direct β-amyloid 25-35 peptide-mediated neurotoxicity in rat hippocampal cultures. J Neurosci Res 1994; 29: 494-505.
39. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995; 45: 1594-1601.
40. Lovell MA, Ehmann WD, Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 1997; 18: 457-461.
41. Manelli AM, Puttfarcken PS. β-Amyloid-induced toxicity in rat hippocampal cells: in vitro evidence for the involvement of free radicals. Brain Res Bull 1995; 38: 569-576.
42. 2+ homeostasis and cell death. J Neurosci 1995; 15: 6239-6349.
43. Mark RJ, Pang Z. Geddes JW, Mattson MP. Amyloid β-peptide impairs glucose uptake in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci 1997; 17: 1046-1054.
44. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP. Evidence that 4-hydroxynonenal mediates disruption of ion homeostasis and neuronal death by amyloid-β peptide. J Neurochem 1997; 68: 255-264.
45. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Rad Biol Med 1997; 23: 134-147.
46. Markesbery WR, Lovell MA. 4-Hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 1998; 19: 33-36.
47. Mattson MP, Goodman Y. Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res 1995; 676: 219-224.
48. Pike C, Burdick D, Walencewicz A, Glabe C, Cotman CW. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 1993; 13: 1676-1686.
49. Prasad MR, Lovell MA, Yatin M, Dhillon HS, Markesbery WR. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 1998; 23: 81-88.
50. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N Engl J Med 1997; 336: 1216-1222.
51. Selkoe DJ. A central role of amyloid. J Neuropathol 1994; 53: 438-447.
52. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer's disease. Proc Natl Acad Sci USA 1991; 88: 10540-10543.
53. Stadtman ER. Protein oxidation and aging. Science 1992; 257: 1220-1224.
54. Subramaniam R, Roediger F, Mattson MP, Keller JN, Waeg G, Butterfield DA. The lipid peroxidation product 4-hydroxy-2-trans-nonenal alters conformation of cortical synaptosomal membrane proteins. J Neurochem 1997; 69: 1161-1169.
55. Subramaniam R, Koppal T, Green M, Yatin S, Jordan B, Drake J, Butterfield DA. The free radical antioxidant vitamin E protects cortical synaptosomal membranes from amyloid β-peptide (25-35) toxicity but not from hydroxynonenal toxicity: Relevance to the free radical hypothesis of Alzheimer's disease. Neurochem Res 1998; 23: 1403-1410.
56. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996; 380: 168-171.
57. Tomiyama T, Shoji A, Kataoka KL, Suwa Y, Asano S, Kaneko K, Endo N. Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicin. J Biol Chem 1996; 271: 6839-6844.
58. 2+ channels: a possible involvement of free radicals. J Neurochem 1997; 68: 265-271.
59. Varadarajan S, Yatin SM, LaFontaine M, Butterfield DA. Soc Neurosci Abstr 1998; 1461.
60. Yatin SM, Aksenov M, Butterfield DA. The antioxidant vitamin E modulates amyloid β-peptide-induced creatine kinase inhibition and increased protein oxidation: Implications for the free radical hypothesis of Alzheimer's disease. Neurochem Res 1999; 24: 427-435.
61. Yatin SM, Aksenova M, Aksenov M, Markesbery WR, Aulick T, Butterfield DA. Temporal relations between amyloid β-peptide-induced free radical oxidative stress and neuronal toxicity and neuronal defensive responses. J Mol Neurosci 1999; in press.
62. Yatin SM, Yatin M, Aulic T, Ain KB Butterfield DA. Alzheimer's amyloid β-peptide generated free radicals increase at embryonic neuronal polyamine uptake and ODC activity: Protective effect of vitamin E. Neurosci Lett 1999; 263: 17-20.
63. Yatin SM, Link CD, Butterfield DA. In-vitro and in-vivo oxidative stress associated with Alzheimer's amyloid β-peptide (1-42). 1999; submitted for publication.
64. Zhou Y, Gopalakrishnam V, Richardson JS. Actions of neurotoxic β-amyloid on calcium homeostasis and viability of PC12 cells are blocked by antioxidants but not by calcium channel antagonists. J Neurochem 1996; 67: 1419-1425.